📚 Part of the Diabetes Landmark Trials guide — every landmark trial in one place.
Series: Landmark Trials in Endocrinology & Metabolism | Study #25
Category: Type 2 Diabetes · Glycaemic Control | Design: Single-blind, randomised controlled trial | n: 1,791 | Follow-up: 5.6 years (median)
📋 Summary
Authors: Duckworth W et al., for the VADT Investigators
Journal: N Engl J Med 2009;360:129–139 | DOI: 10.1056/NEJMoa0808431
The Veterans Affairs Diabetes Trial enrolled 1,791 US military veterans (mean age 60.4 years) with type 2 diabetes mellitus who had a suboptimal response to existing therapy, with 40% having had a prior cardiovascular event and a mean diabetes duration of 11.5 years. Participants were randomly assigned to intensive or standard glucose control, with other cardiovascular risk factors treated uniformly in both groups. The intensive therapy goal was an absolute HbA1c reduction of 1.5 percentage points from baseline; stable median HbA1c levels of 6.9% and 8.4% were achieved in the intensive and standard groups respectively. The primary outcome was the composite of nonfatal MI, stroke, cardiovascular death, congestive heart failure, revascularisation, and amputation for ischaemic gangrene. After a median follow-up of 5.6 years, the primary composite occurred in 235 patients in the intensive-therapy group and 264 in the standard-therapy group (HR 0.88; 95% CI 0.74 to 1.05; p=0.14), a non-significant reduction. There were no significant differences in individual cardiovascular components, all-cause mortality (HR 1.07; 0.81 to 1.42; p=0.62), or microvascular complications, with the exception of a significant reduction in progression of albuminuria with intensive therapy (p=0.01). Adverse events, primarily hypoglycaemia, occurred in 17.6% of the standard group and 24.1% of the intensive group.
📊 Key Findings
| Outcome | Intensive | Standard | Effect Size |
|---|---|---|---|
| Primary composite CV event | 235 | 264 | HR 0.88 (0.74–1.05) · p=0.14 · NS |
| All-cause mortality | — | — | HR 1.07 (0.81–1.42) · NS (no harm) |
| Microvascular complications | — | — | No significant difference |
| Albuminuria progression | — | — | Reduced with intensive therapy · p=0.01 |
| HbA1c achieved | 6.9% | 8.4% | Difference −1.5% |
| Hypoglycaemia adverse events | 24.1% | 17.6% | Increased with intensive therapy |
VADT: Intensive Glucose Control
RCT · long-standing type 2 diabetes · 5.6 years
Intensive glucose control to a mean HbA1c of 6.9% did not significantly reduce cardiovascular events or mortality in veterans with long-standing high-risk type 2 diabetes, completing the ACCORD/ADVANCE/VADT triptych.
💬 Expert Commentary
VADT was the third of the three pivotal intensive glucose-lowering trials published in 2008–2009, and its null result for cardiovascular endpoints consolidated the evidence from ACCORD and ADVANCE that intensive glucose reduction does not produce cardiovascular benefit in patients with long-standing type 2 diabetes and high cardiovascular risk, at least within a 5-year timeframe. The VADT population was distinctive: predominantly male veterans with a mean diabetes duration of 11.5 years and a high prior cardiovascular event rate (40%), representing a population with advanced disease in whom atherosclerotic plaques are already well established and unlikely to be significantly regressed by metabolic improvement over a few years. This context is central to interpreting the null result. Post-hoc subgroup analyses from VADT subsequently showed that patients with less coronary artery calcium burden at baseline derived greater relative benefit from intensive glycaemic control than those with heavy calcification, suggesting that the population enrolled in VADT may have been too advanced in their cardiovascular disease for glucose lowering to produce detectable benefit.
VADT, unlike ACCORD, did not demonstrate a mortality hazard — HR 1.07 with a wide confidence interval spanning substantial benefit and harm. This is an important distinction: VADT and ADVANCE suggest that intensive glucose lowering is metabolically neutral for cardiovascular risk in high-risk patients with long disease duration, while ACCORD suggests it may be harmful in a specific combination of population, strategy, and drug regimen. The three trials collectively informed the modern concept that the cardiovascular benefit of glycaemic improvement is greatest in the early years of diabetes, in patients without established atherosclerotic disease, and with moderate rather than extreme targets, whereas aggressive glucose lowering in patients with advanced and calcified coronary disease may offer little benefit and carries risk of hypoglycaemia-related harm.
Limitations: Single-blind design. High-risk veterans population may not represent the broader type 2 diabetes population. High baseline cardiovascular disease burden may have limited the potential for benefit. The study was funded by the US Department of Veterans Affairs and NIH.
🔑 BOTTOM LINE
VADT demonstrated that intensive glucose control achieving a mean HbA1c of 6.9% did not significantly reduce cardiovascular events or mortality in military veterans with long-standing type 2 diabetes and high prior cardiovascular event rates, completing the ACCORD/ADVANCE/VADT triptych that established the limits of glucose-centric cardiovascular risk management in advanced type 2 diabetes.
⭐ Clinical Impact Rating: ●●●●○ Practice-changing (alongside ACCORD and ADVANCE)